Drug Profile
Research programme: histamine H3 receptor antagonists - Evotec SE
Alternative Names: EVT-501Latest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer Evotec SE
- Class Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cognition disorders; Narcolepsy; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Narcolepsy in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany